10:41 AM EST - Oncolytics Biotech Inc : Today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board. The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute, Germany's medical regulatory body. The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. Oncolytics Biotech Inc
shares T.ONC are trading up one cent at $2.00.
